The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia
Abstract
Despite intense investigation, mechanisms that facilitate the emergence of the pre-eclampsia phenotype in women are still unknown. Placental hypoxia, hypertension, proteinuria and oedema are the principal clinical features of this disease. It is speculated that hypoxia-driven disruption of the angiogenic balance involving vascular endothelial growth factor (VEGF)/placenta-derived growth factor (PLGF) and soluble Fms-like tyrosine kinase-1 (sFLT-1, the soluble form of VEGF receptor 1) might contribute to some of the maternal symptoms of pre-eclampsia. However, pre-eclampsia does not develop in all women with high sFLT-1 or low PLGF levels, and it also occurs in some women with low sFLT-1 and high PLGF levels. Moreover, recent experiments strongly suggest that several soluble factors affecting the vasculature are probably elevated because of placental hypoxia in the pre-eclamptic women, indicating that upstream molecular defect(s) may contribute to pre-eclampsia. Here we show that pregnant mice deficient in catechol-O-methyltransferase (COMT) show a pre-eclampsia-like phenotype resulting from an absence of 2-methoxyoestradiol (2-ME), a natural metabolite of oestradiol that is elevated during the third trimester of normal human pregnancy. 2-ME ameliorates all pre-eclampsia-like features without toxicity in the Comt(-/-) pregnant mice and suppresses placental hypoxia, hypoxia-inducible factor-1alpha expression and sFLT-1 elevation. The levels of COMT and 2-ME are significantly lower in women with severe pre-eclampsia. Our studies identify a genetic mouse model for pre-eclampsia and suggest that 2-ME may have utility as a plasma and urine diagnostic marker for this disease, and may also serve as a therapeutic supplement to prevent or treat this disorder.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, succinate is also an inhibitor of HIF-1α(213), which has been implicated in the exaggerated production of sFlt-1 and in the pathophysiology of preeclampsia(214, 215)”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [214]
Citations
Cites
Maynard, S. E., Min, J.-Y., Merchan, J., Lim, K.-H., Li, J., Mondal, S., Libermann, T. A., Morgan, J. P., Sellke, F. W., Stillman, I. E., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17189 · Cited by 4,101
Circulating angiogenic factors and the risk of preeclampsia
Levine, R. J., Maynard, S. E., Qian, C., Lim, K.-H., England, L. J., Yu, K. F., Schisterman, E. F., Thadhani, R., Sachs, B. P., Epstein, F. H., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031884 · Cited by 3,720
Circulating angiogenic factors and the risk of preeclampsia*
(2004) · Obstetrics and Gynecology · doi:10.1097/00006250-200405000-00028 · Cited by 2,623
Latest Advances in Understanding Preeclampsia
Redman, C. W., & Sargent, I. L. (2005) · Science · doi:10.1126/science.1111726 · Cited by 2,607
Hypoxia-inducible factor 1: master regulator of O2 homeostasis
Semenza, G. L. (1998) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(98)80016-6 · Cited by 1,092
Gogos, J. A., Morgan, M., Luine, V., Santha, M., Ogawa, S., Pfaff, D., & Karayiorgou, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.17.9991 · Cited by 864
Fotsis, T., Zhang, Y., Pepper, M. S., Adlercreutz, H., Montesano, R., Nawroth, P. P., & Schweigerer, L. (1994) · Nature · doi:10.1038/368237a0 · Cited by 730
2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF
Mabjeesh, N. J., Escuin, D., LaVallee, T. M., Pribluda, V. S., Swartz, G. M., Johnson, M. S., Willard, M. T., Zhong, H., Simons, J. W., & Giannakakou, P. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00077-1 · Cited by 730
Caniggia, I., Mostachfi, H., Winter, J., Gassmann, M., Lye, S. J., Kuliszewski, M., & Post, M. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8316 · Cited by 644
Genbačev, O., Joslin, R. J., Damsky, C. H., Polliotti, B., & Fisher, S. J. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118447 · Cited by 577
Cited by
Sorted by citations
Rana (2019) · doi:10.1161/circresaha.118.313276 · Cited by 2,095
Pre-eclampsia: pathogenesis, novel diagnostics and therapies
Phipps, E. A., Thadhani, R., Benzing, T. R., & Karumanchi, S. A. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0119-6 · Cited by 1,328
Preeclampsia, a Disease of the Maternal Endothelium
Powe, C. E., Levine, R. J., & Karumanchi, S. A. (2011) · Circulation · doi:10.1161/circulationaha.109.853127 · Cited by 987
Pre-eclampsia part 1: current understanding of its pathophysiology
Chaiworapongsa, T., Chaemsaithong, P., Yeo, L., & Romero, R. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.102 · Cited by 956
Challis, J. R., Lockwood, C. J., Myatt, L., Norman, J. E., Strauss, J. F., & Petraglia, F. (2009) · Reproductive Sciences · doi:10.1177/1933719108329095 · Cited by 893
Metadata
- Authors
- Kanasaki, K., Palmsten, K., Sugimoto, H., Ahmad, S., Hamano, Y., Xie, L., Parry, S., Augustin, H. G., Gattone, V. H., Folkman, J., Strauss, J. F., & Kalluri, R.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Birmingham Women's Hospital (GB)
- University of Pennsylvania (US)
- German Cancer Research Center (DE)
- Indiana University Indianapolis (US)
- Boston Children's Hospital (US)
- Virginia Commonwealth University (US)
- Corresponding author
- Kalluri, Raghu
- ORCID
- Venue
- Nature
- Published
- 2008-05-11
- Volume
- 453
- Issue
- 7198
- Pages
- 1117-1121
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2066278927
- Cited by
- 381
- References
- 34
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 8 · 2023: 8 · 2022: 13 · 2021: 18 · 2020: 22 · 2019: 27 · 2018: 28 · 2017: 31 · 2016: 16 · 2015: 22 · 2014: 29 · 2013: 22 · 2012: 29
- FWCI
- 34.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- Beth Israel Deaconess Medical Center
- University of Pennsylvania
- British Heart Foundation
- Fondation pour la Recherche Médicale
- Georg-August-Universität Göttingen
- Kanae Foundation for the Promotion of Medical Science
- National Institutes of Health
- Medical Research Council
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 62987, DK61688, R01DK062987, DK 13193, DK-55001, R01DK061688, R01DK055001)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Pregnancy and preeclampsia studies
- Health Sciences › Medicine › Clinical Neurology › Neurological Complications and Syndromes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
- Keywords
- preeclampsia, catechol-O-methyltransferase, 2-methoxyestradiol, placental hypoxia, angiogenic imbalance, soluble fms-like tyrosine kinase-1, vascular endothelial growth factor, placental growth factor, placenta, pregnancy complications, therapeutic target, proteinuria, hypertension, edema
- MeSH terms
- 2-Methoxyestradiol, Albumins, Animals, Hypoxia, Blood Pressure, Catechol O-Methyltransferase, Creatinine, Disease Models, Animal, Estradiol, Female, Humans, Hypertension, Killer Cells, Natural, Litter Size, Male, Placenta, Pre-Eclampsia, Pregnancy, Proteinuria, Vascular Endothelial Growth Factor Receptor-1, Mice, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
